Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label study.
Ontology highlight
ABSTRACT: Six patients from the phase 3 trials of zoledronic acid in Paget's disease, who had received zoledronic acid initially and had subsequently relapsed, were entered into an open re-treatment study. Following re-treatment, each patient reached similar absolute nadirs of serum alkaline phosphatase to those recorded after their first dose. No significant adverse events were reported. It is concluded that, while re-treatment of Paget's disease with zoledronic acid is rarely needed, it is safe and effective, with no evidence of treatment resistance based on this small cohort.
SUBMITTER: Reid IR
PROVIDER: S-EPMC3844974 | biostudies-literature | 2013
REPOSITORIES: biostudies-literature
ACCESS DATA